Baricitinib Patent Expiration

Baricitinib is Used for treating severe alopecia areata, COVID-19 in hospitalized adults requiring supplemental oxygen, ventilation, or ECMO, and rheumatoid arthritis. It was first introduced by Eli Lilly And Co in its drug Olumiant on May 31, 2018. 2 different companies have introduced drugs containing Baricitinib.


Baricitinib Patents

Given below is the list of patents protecting Baricitinib, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Olumiant US11045474 Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections Nov 30, 2032 Eli Lilly And Co
Olumiant US9089574 Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections Nov 30, 2032 Eli Lilly And Co
Olumiant US8158616 Azetidine and cyclobutane derivatives as JAK inhibitors May 31, 2032 Eli Lilly And Co
Olumiant US11806555 Methods for treating hair loss disorders Nov 02, 2031 Eli Lilly And Co
Olumiant US9737469 Methods for treating hair loss disorders Nov 02, 2031 Eli Lilly And Co
Olumiant US8420629 Azetidine and cyclobutane derivatives as JAK inhibitors Mar 10, 2029 Eli Lilly And Co



Baricitinib's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Baricitinib Generic API Manufacturers

Several generic applications have been filed for Baricitinib.

Given below is the list of companies who have filed for Baricitinib generic, along with the locations of their manufacturing plants worldwide.


1. AUROBINDO PHARMA LTD

Aurobindo Pharma Ltd has filed for 2 different strengths of generic version for Baricitinib. Given below are the details of the strengths of this generic introduced by Aurobindo Pharma Ltd.

Strength Dosage Form Availability Application Pathway TE code Launch Date
1MG

tablet Discontinued ORAL N/A Jul 22, 2024
2MG

tablet Discontinued ORAL N/A Jul 22, 2024


Manufacturing Plant Locations
New

Aurobindo Pharma Ltd's manufacturing plants are situated in 1 country - India. Given below are the details of these plant locations as well as the firm names of Aurobindo Pharma Ltd as present at those locations.

Country City Firm Name
India
Medchal Aurobindo Pharma Ltd